EP1893585A1 - Procede de preparation de n-[4-(4-fluorophenyl)-5-formyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethanesulfonamide - Google Patents

Procede de preparation de n-[4-(4-fluorophenyl)-5-formyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethanesulfonamide

Info

Publication number
EP1893585A1
EP1893585A1 EP06755392A EP06755392A EP1893585A1 EP 1893585 A1 EP1893585 A1 EP 1893585A1 EP 06755392 A EP06755392 A EP 06755392A EP 06755392 A EP06755392 A EP 06755392A EP 1893585 A1 EP1893585 A1 EP 1893585A1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
halogen
protecting group
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06755392A
Other languages
German (de)
English (en)
Inventor
Arne Grumann
Pekka PIETIKÄINEN
Inese Reine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fermion Oy
Original Assignee
Fermion Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20050586A external-priority patent/FI20050586A0/fi
Application filed by Fermion Oy filed Critical Fermion Oy
Publication of EP1893585A1 publication Critical patent/EP1893585A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals

Definitions

  • the present invention is directed to a method for the preparation of N-[4-(4- fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl]-N-methylmethanesulfonamide having a structure of formula I
  • Rosuvastatin is a HMG-CoA reductase inhibitor used as a calcium salt in the treatment of hypercholesterolemia, hyperlipodemia and atherosclerosis. Its chemical name is (+)-(3R,5S)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N- methylsulfonylamino)-pyrimidin-5-yl]-3,5-dihydroxy-6(E)heptenoic acid.
  • Other statins used as lipid-lowering drugs are e.g. simvastatin, atorvastatin, lovastatin and pravastatin.
  • Rosuvastatin and a process for its preparation is disclosed in US patent no 5,260,440.
  • the preparation process described contains four steps: a) condensation of methyl (3R)-3-[tert-butylmethylsilyl)-oxy]-5-oxo-6-triphenylphosphoranylidene hexanoate with N-[4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl]-N- methylmethanesulfonamide, b) deprotection of the 3-hydroxyl group to give the keto alcohol, c) reduction of 5-oxo to obtain the chiral dihydroxy heptenate, and d) hydrolysis of the dihydroxy heptenate.
  • N-[4-(4-fluorophenyl)-5- formyl-6-isopropylpyrimidin-2-yl]-N-methylmethanesulfonamide (referred later as pyrimidine compound) is prepared from 4-fluorobenzaldehyde, 4-methyl-3-oxo- pentanoic acid ethyl ester and S-methylisothiourea.
  • the preparation of the pyrimidine compound requires eight synthetic steps and involves the use of expensive and hazardous reagents and solvents like 2,3-dichloro-5,6-dicyano-l,4-benzoquinone, m- chloroperoxybenzoic acid, tetrapropylammonium perruthenate, and hexamethylphosphoramide. Also, the pyrimidine compound is obtained only in moderate yield.
  • the starting material for rosuvastatin, N- [4-(4-fluorophenyl)-5 -formyl-6-isopropylpyrimidin-2-yl] -N-methylmethane- sulfonamide can be prepared economically starting from 2,4,6- trihalogenopyrimidme-5-carbaldehyde, which can be made from 2,4,6- trioxohexahydropyrimidine (barbituric acid) or from 2,4,6-trihalogenopyrirnidine.
  • One aspect of the present invention is the process for the preparation of a compound of formula I
  • Rl is OR5 or SR5 and R2 is OR5 or SR5 or NR5 and R5 is substituted or non substituted alkyl chain and they together form a linear or cyclic aldehyde protecting group and N-R4 is an aldehyde protecting group wherein R4 is e.g. NMe 2 , OMe or OBn.
  • Another aspect of the present invention is the reaction of the the pyrimidine compound of formula I prepared according to the invention to produce rosuvastatin or a pharmaceutically acceptable salt thereof.
  • the first step is the addition of a suitable group to protect the aldehyde.
  • Suitable protective groups as well as processes for their addition are described in textbooks, e.g. in Greene and Wuts (T. W. Greene and P.G.M. Wuts, Protective groups in organic synthesis, John Wiley & Sons, Inc., 3 rd . ed, New York, 1999), which is incorporated here as a reference, hi the process of the invention the preferable groups used are e.g. acyclic or cyclic acetal, monothioacetal or dithioacetal. If e.g.
  • 1,3-dioxolane (cyclic acetal), is used as a protective group
  • the process maybe the following: 2,4,6-trihalogenopyrimidine-5-carbaldehyde is dissolved in a suitable organic solvent, which can be e.g. an aromatic hydrocarbon or ethylene glycol or a mixture thereof, or the reagent, like ethylene glycol, may be used as a solvent.
  • a suitable organic solvent which can be e.g. an aromatic hydrocarbon or ethylene glycol or a mixture thereof, or the reagent, like ethylene glycol, may be used as a solvent.
  • Acid catalyst e.g. Lewis acid or protic acid may be used in the reaction.
  • the mixture is typically reacted at ambient or reflux temperature for the process to complete, and thereafter the product is isolated and purified using the methods known in the art.
  • the product from the previous step is dissolved in a suitable organic solvent, e.g. ethers like tetrahydrofuran, aromatic hydrocarbons like toluene or xylene, aprotic polar solvents like N-methylpyrrolidinone or mixtures thereof may be used.
  • a suitable organic solvent e.g. ethers like tetrahydrofuran, aromatic hydrocarbons like toluene or xylene, aprotic polar solvents like N-methylpyrrolidinone or mixtures thereof may be used.
  • the isopropyl group can be added using an isopropyl metallic compound, such as an isopropyl magnesium halide, e.g. bromide or chloride using transition metal catalysis e.g. Fe, Ni or Cu compounds can be used, preferably Li 2 CuCl 4 is used as a catalyst.
  • An aqueous work up and purification as known in the art, such as column chromatography or crystallization may be used
  • the process may be continued in one pot to step c) without isolation of the intermediate from step b).
  • Compound of formula IV is reacted with a 4-fluorophenyl metallic compound (4-F-C 6 H 4 -M) in a suitable solvent, e.g. ethers like tetrahydrofuran, nonpolar hydrocarbons like toluene or xylene, polar double or triple bond containing solvents like acetonitrile, other polar aprotic solvents like N,N-dimethylformamide, and polar protic solvents like alcohols or water or mixtures thereof may be used.
  • Suitable metallic substituents (M) include e.g.
  • Non-metallic substituents (M) like Si can also be used in this reaction step.
  • the reaction maybe catalyzed by transition metal catalysts e.g. Fe, Ni, Cu or Pd compounds, preferably Pd(H) or Pd(O) compounds are used.
  • An aqueous work up and purification as known in the art such as column chromatography or crystallization may be used to provide the adduct in good purity.
  • a compound of formula V is reacted with N-methylmethanesulfonamide or its anion in a suitable solvent.
  • the anion can be formed with a suitable base, which can be e.g. carbonate, hydroxide, alkoxide, hydride, amidine, or alkylmetal compound.
  • Suitable solvent is dependent on the base used, e.g. ethers, aprotic polar solvents, aromatic or aliphatic hydrocarbons or mixtures thereof can be used.
  • Typical base-solvent combinations include e.g.
  • Aldehyde protection made in step a) is removed by a suitable method known in the art to obtain a compound of formula I.
  • the starting compound of formula II can be made starting from barbituric acid or from 2,4,6-trihalogeno pyrimidine, which are commercially available compounds.
  • 2,4,6-trichloropyrimidine-5-carbaldehyde can be made from barbituric acid in one pot reaction e.g. in the following way.
  • Barbituric acid is reacted with suitable chlorinating and formylating agents in a suitable solvent to obtain 2,4,6-trichloropyrimidine-5-carbaldehyde.
  • suitable solvents may be e.g. polar aprotic or aromatic hydrocarbons like toluene or xylene, chlorinated hydrocarbons like 1,2-dichloroethane or chlorobenzene.
  • Possible chlorinating agents include but are not limited to POCl 3 , SOCl 2 , PCl 3 , PCl 5 , COCl 2 , or (COCl) 2 and as formylating agent e.g.
  • formamides like ⁇ iV-dimethylformamide, iV-methylformanilide, iV-formylpiperidine, N-formylmo ⁇ holine or other amides like A ⁇ JV-dimethylacetamide, N-methylpyrrolidone, N,N, dimethylbenzamide may be used.
  • Reaction temperature and time depend on the solvent used, e.g. reflux temperature may be used. Remaining halogenating agent is removed and the resulting 2,4,6-trichloropyrimidine-5-carbaldehyde may be isolated and purified by methods known in the art.
  • Compound of formula II may also be made in two steps comprising chlorination using the chlorinating agents as mentioned above and formylation separately by some method known in the art, or it may be obtained by formylation of commercially available halogenated compound of formula II by some methods known in the art, e.g. using n-butyllithium/ N,iV-dmiethylformamide, lithium diisopropylamide/ethylformate, and hexamethylenetetramine.
  • Chlorinated compound of formula II is the preferred compound used, but also other halogens can be used. e.g. bromo-compound may be made using e.g. PBr 3 as a halogenating agent.
  • 2,4,6-Trichloro-5 -[1,3] dioxolane-2-ylpyrimidine To the solution of 2,4,6-trichloropyrimidine-5-carbaldehyde (10.0 g) in dry benzene (200 ml) were added ethylene glycol (8.0 ml) andp-toluenesulfonic acid (0.15 g). The mixture was refluxed for 20 h, the warm benzene layer was decanted and the residue was washed with warm benzene (2x50 ml). Combined benzene solution was evaporated, water (30 ml) was added and the suspension formed was neutralized with 9% NaHCO 3 . The precipitate was filtered to afford 10.3 g (85%) of 2,4,6-trichloro-5- [l,3]dioxolane-2-ylpyrimidine, m.p. 161-162 0 C.
  • This organozinc solution was added to a mixture of 2,4-dichloro-5- [l,3]dioxolane-2-yl-6-isopropylpyrimidine (0.5 g) and Pd(PPh 3 ) 4 (1 mol-%, 13 mg) in THF (15 ml).
  • the reaction mixture was heated at 55-60 0 C for 4.5 h. After cooling it was poured in 10% NH 4 Cl — ice mixture.
  • the organic layer was separated and aqueous phase was extracted with ethyl acetate (2x20 ml).
  • the combined organic extract was washed with 10% aq EDTA (15 ml) and saturated NaCl solution, and evaporated.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne une méthode pour préparer du N-[4-(4-fluorophényl)-5-formyl-6-isopropylpyrimidin-2-yl]-N-méthylméthanesulfonamide et l'utilisation de celui-ci pour préparer de la rosuvastatine ou un sel pharmaceutiquement acceptable de celle-ci.
EP06755392A 2005-06-01 2006-05-31 Procede de preparation de n-[4-(4-fluorophenyl)-5-formyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethanesulfonamide Withdrawn EP1893585A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68589005P 2005-06-01 2005-06-01
FI20050586A FI20050586A0 (fi) 2005-06-01 2005-06-01 Menetelmä N-[4-(4-fluorofenyyli)-5-formyyli-6-isopropyylipyrimidiini-2-yyli]-N-metyylimetaanisulfonamidin valmistamiseksi
PCT/FI2006/000170 WO2006128954A1 (fr) 2005-06-01 2006-05-31 Procede de preparation de n-[4-(4-fluorophenyl)-5-formyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethanesulfonamide

Publications (1)

Publication Number Publication Date
EP1893585A1 true EP1893585A1 (fr) 2008-03-05

Family

ID=37056773

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06755392A Withdrawn EP1893585A1 (fr) 2005-06-01 2006-05-31 Procede de preparation de n-[4-(4-fluorophenyl)-5-formyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethanesulfonamide

Country Status (2)

Country Link
EP (1) EP1893585A1 (fr)
WO (1) WO2006128954A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008072078A1 (fr) 2006-12-13 2008-06-19 Aurobindo Pharma Limited Procédé amélioré de préparation de calcium de rosuvastatine
EP2178847A2 (fr) * 2007-08-20 2010-04-28 Ratiopharm GmbH Procédé de préparation de dérivés de pyrimidine
EP2752407B1 (fr) 2009-01-14 2015-09-23 Krka Tovarna Zdravil, D.D., Novo Mesto Sel de calcium trihydrate de rosuvastatine cristallisé
CN105622522B (zh) * 2014-12-01 2018-01-16 重庆安格龙翔医药科技有限公司 一种瑞舒伐他汀钙关键中间体的合成方法
CN105622521B (zh) * 2014-12-01 2018-01-16 重庆安格龙翔医药科技有限公司 一种瑞舒伐他汀钙关键中间体的制备方法
CN105712939B (zh) * 2014-12-01 2018-01-23 重庆安格龙翔医药科技有限公司 一种合成瑞舒伐他汀钙关键中间体的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT328414B (de) * 1972-03-03 1976-03-25 Gerot Pharmazeutika Verfahren zur herstellung von 4,6-dichlor-pyrazolo- (3,4-d) -pyrimidin bzw. dessen neuen 1-aryl- oder 1-aralkylderivaten
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
EP1585736A2 (fr) * 2002-05-21 2005-10-19 Ranbaxy Laboratories, Ltd. Procede de preparation de rosuvastatine
ATE501126T1 (de) * 2002-12-10 2011-03-15 Ranbaxy Lab Ltd Verfahren zur herstellung von rosuvastatin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006128954A1 *

Also Published As

Publication number Publication date
WO2006128954A1 (fr) 2006-12-07

Similar Documents

Publication Publication Date Title
AU2002318041B2 (en) Preparation of aminopyrimidine compounds
AU2006268024B2 (en) Processes for the manufacture of rosuvastatin and intermediates
US20080188657A1 (en) Chemical process
CN101084197B (zh) 制备罗苏伐他汀的方法
CN102459146A (zh) 制备苯并呋喃的方法
US8394956B2 (en) Process for preparing pyrimidine propenaldehyde
CA2646795A1 (fr) Procede de preparation du bosentan
WO2008072078A1 (fr) Procédé amélioré de préparation de calcium de rosuvastatine
EP1893585A1 (fr) Procede de preparation de n-[4-(4-fluorophenyl)-5-formyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethanesulfonamide
JP4649813B2 (ja) ２−アミノ−４−（４−フルオロフェニル）−６−アルキルピリミジン−５−カルボキシレートの製造方法
EP2576518B1 (fr) Procédé amélioré pour la préparation d'intermédiaire propénal et dérivés de celui-ci
EP0990647A1 (fr) Procede de production de derives de quinolone
KR101528359B1 (ko) 스타틴 화합물 제조를 위한 신규한 보로네이트 에테르 화합물, 그 제조방법 및 상기 보로네이트 에테르 화합물을 이용한 스타틴 화합물 제조방법
EP0347866B1 (fr) Dérivés d'anilino-pyrimidines
HK1160468A (en) Process for preparing rosuvastatin
JP2008518996A (ja) ピリミジン−５−カルボキシレートの生成方法
HK1064384B (en) Preparation of aminopyrimidine compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

17Q First examination report despatched

Effective date: 20080327

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090505